Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
Editor's Choice
LIPID DISORDERS / GUIDELINES/RECOMMENDATIONS
2024 Polish recommendations for the management of familial hypercholesterolemia in children and adolescents
1
Department of Pediatrics, Diabetology and Endocrinology, Medical University of Gdansk, Gdansk, Poland
2
Department of Pediatrics, Endocrinology, Diabetology, Metabolic Diseases and Cardiology of Developmental Age, Pomeranian Medical University, Szczecin, Poland
3
Department of Pediatrics, Oncology and Pediatric Immunology, Pomeranian Medical University, Szczecin, Poland
4
Department of Inborn Errors of Metabolism and Pediatrics, Institute of Mother and Child, Warsaw, Poland
5
Department of Cardiology, Children's Memorial Health Institute, Warsaw, Poland
6
1st Department of Cardiology, Medical University of Gdansk, Poland
7
Department of Biology and Medical Genetics, Medical University of Gdansk, Gdansk, Poland
8
Laboratory of Clinical Genetics, University Clinical Centre, Gdansk, Poland
9
Department of Clinical Genetics, Medical University of Lodz, Poland
10
Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Poland
11
Ciccarone Center for the Prevention of Cardiovascular Disease, School of Medicine, Johns Hopkins University, Baltimore, MD, USA
12
Center for the Atherosclerosis and Cardiovascular Diseases Prevention, Faculty of Medicine, John Paul II Catholic University of Lublin, Poland
Submission date: 2024-08-24
Final revision date: 2024-11-22
Acceptance date: 2024-11-22
Online publication date: 2024-11-22
Corresponding author
Małgorzata Myśliwiec
Department of Pediatrics, Diabetology and Endocrinology, Medical University of Gdansk, Gdansk, Poland, Debinki, 80-211, Gdansk, Poland
Department of Pediatrics, Diabetology and Endocrinology, Medical University of Gdansk, Gdansk, Poland, Debinki, 80-211, Gdansk, Poland
KEYWORDS
TOPICS
ABSTRACT
Familial hypercholesterolemia (FH) is the most common monogenic disease leading to the accelerated development of atherosclerotic cardiovascular disease (ASCVD). Despite increasing medical knowledge, diagnostic testing, and a growing number of therapeutic options, the effectiveness of detecting and treating FH remains highly insufficient. Only early detection (as early as possible) and optimal treatment in pediatric patients will lead to a significant reduction in morbidity and mortality from atherosclerotic cardiovascular disease (ASCVD) in later years. We present the guidelines for the management of FH in children and adolescents in Poland. This document is an update of the 2014 Position Paper of the Lipid Expert Forum.
REFERENCES (83)
1.
Beheshti SO, Madsen CM, Varbo A, Nordestgaard BG. Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects. J Am Coll Cardiol 2020; 75: 2553-66.
2.
Nordestgaard BG, Chapman MJ, Humphries SE, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J 2013; 34: 3478-90.
3.
Juonala M, Viikari JSA, Rönnemaa T, et al. Associations of dyslipidemias from childhood to adulthood with carotid intima-media thickness, elasticity, and brachial flow-mediated dilatation in adulthood: the Cardiovascular Risk in Young Finns Study. Arterioscler Thromb Vasc Biol 2008; 28: 1012-7.
4.
Raitakari OT, Juonala M, Kähönen M, et al. Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study. JAMA 2003; 290: 2277-83.
5.
Vallejo-Vaz AJ, Marco M De, Stevens CAT, et al. Overview of the current status of familial hypercholesterolaemia care in over 60 countries – The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Atherosclerosis 2018; 277: 234-55.
6.
Vallejo-Vaz AJ, Stevens CAT, Lyons ARM, et al. Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). Lancet 2021; 398: 1713-25.
7.
Lewek J, Konopka A, Starostecka E, Penson PE, Maciejewski M, Banach M. Clinical features of familial hypercholesterolemia in children and adults in EAS-FHSC Regional Center for Rare Diseases in Poland. J Clin Med 2021; 10: 4302.
8.
Yu Y, Chen L, Zhang H, et al. Association between familial hypercholesterolemia and risk of cardiovascular events and death in different cohorts: a meta-analysis of 1.1 million subjects. Front Cardiovasc Med 2022; 9: 860196.
9.
Wang X, Cai G, Wang Y, et al. Comparison of long-term outcomes of young patients after a coronary event associated with familial hypercholesterolemia. Lipids Health Dis 2019; 18: 131.
10.
Tokgozoglu L, Kayikcioglu M. familial hypercholesterolemia: global burden and approaches. Curr Cardiol Rep 2021; 23: 151.
11.
Banach M, Burchardt P, Chlebus K, et al. Wytyczne PTL/KLRwP/PTK/PTDL/PTD/PTNT diagnostyki i leczenia zaburzeń lipidowych w Polsce 2021. Lekarz POZ Suplement 2021; 4: 1-111.
12.
Myśliwiec M, Walczak M, Małecka-Tendera E, et al. Management of familial hypercholesterolemia in children and adolescents. Position paper of the Polish Lipid Expert Forum. J Clin Lipidol 2014; 8: 173-80.
13.
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis 2019; 290: 140-205.
14.
Anagnostis P, Antza C, Florentin M, Kotsis V. Familial hypercholesterolemia and its manifestations: Practical considerations for general practitioners. Pol Heart J 2023; 81: 1081-8.
15.
Ison HE, Clarke SL, Knowles JW, et al. Familial Hypercholesterolemia. GeneReviews® 2022 Jul 7; Available from: https://www.ncbi.nlm.nih.gov/b....
16.
Chmara M, Zuk M, Mickiewicz A, et al. Molecular basis of familial hypercholesterolemia in Poland – update from the Polish national centre of diagnostics and treatment of familial hypercholesterolemia. Atherosclerosis 2016; 252: e38.
17.
Kubalska J, Chmara M, Limon J, et al. Clinical course of homozygous familial hypercholesterolemia during childhood: report on 4 unrelated patients with homozygous or compound heterozygous mutations in the LDLR gene. J Appl Genet 2008; 49: 109-13.
18.
Chlebus K, Żarczyńska-Buchowiecka M, Pajkowski M, Chmara M, Tromp TR, Gruchała M. Homozygous familial hypercholesterolemia due to APOB genetic variant with unusual clinical course. Pol Heart J 2021; 79: 1030-1.
19.
Chlebus K, Cybulska B, Gruchała M, et al. Prevalence, diagnosis, and treatment of familial hypercholesterolaemia in outpatient practices in Poland. Pol Heart J 2018; 76: 960-7.
20.
Pajak A, Szafraniec K, Polak M, et al. Prevalence of familial hypercholesterolemia: a meta-analysis of six large, observational, population-based studies in Poland. Arch Med Sci 2016; 12: 687-96.
21.
Banach M, Jankowski P, Joíwiak J, et al. PoLA/CFPiP/PCS guidelines for the management of dyslipidaemias for family physicians 2016. Arch Med Sci 2017; 13: 1-45.
22.
Fellin R, Arca M, Zuliani G, Calandra S, Bertolini S. The history of autosomal recessive hypercholesterolemia (ARH). From clinical observations to gene identification. Gene 2015; 555: 23-32.
23.
Talmud PJ, Shah S, Whittall R, et al. Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet 2013; 381: 1293-301.
24.
Averna MR, Cefalù AB. Lp(a): a genetic cause of clinical FH in children. Eur Heart J 2023; 44: 1429-31.
25.
Varghese MJ. Familial hypercholesterolemia: a review. Ann Pediatr Cardiol 2014; 7: 107-17.
26.
Tromp TR, Hartgers ML, Hovingh GK, et al. Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study. Lancet 2022; 399: 719-28.
27.
Di Taranto MD, Giacobbe C, Fortunato G. Familial hypercholesterolemia: a complex genetic disease with variable phenotypes. Eur J Med Genet 2020; 63: 103831.
28.
Idzior-Waluś B, Sanak M, Starzyk J, Czarnecka D, Waluś-Miarka M. Autosomalna dominująca hipercholesterolemia: niedoceniony problem diagnostyczny i kliniczny. Kardiol Pol 2009; 67: 1015-22.
29.
Fahed AC, Wang M, Patel AP, et al. Association of the interaction between familial hypercholesterolemia variants and adherence to a healthy lifestyle with risk of coronary artery disease. JAMA Netw Open 2022; 5: e222687.
30.
Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients. Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5 (3 suppl): S1-8.
31.
Nielsen ST, Lytsen RM, Strandkjaer N, et al. Significance of lipids, lipoproteins, and apolipoproteins during the first 14-16 months of life. Eur Heart J 2023; 44: 4408-18.
32.
Lauer RM, Barness LA, Clark R, et al. National Cholesterol Education Program (NCEP): highlights of the Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992; 89: 495-501.
33.
Kwiterovich PO. Recognition and management of dyslipidemia in children and adolescents. J Clin Endocrinol Metab 2008; 93: 4200-9.
34.
Sosnowska B, Stepinska J, Mitkowski P, et al. Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels. Arch Med Sci 2024; 20: 8-27.
35.
Langlois MR, Chapman MJ, Cobbaert C, et al. Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A Consensus Statement from EAS and EFLM. Clin Chem 2018; 64: 1006-33.
36.
Chidambaram V, Kumar A, Majella MG, et al. HDL cholesterol levels and susceptibility to COVID-19. EBioMedicine 2022; 82: 104166.
37.
Daniels SR, Greer FR. Lipid screening and cardiovascular health in childhood. Pediatrics 2008; 122: 198-208.
38.
Gidding SS. To screen or not to screen: that is the cholesterol question. Pediatrics 2024; 154: e2024068548.
39.
Iwańczak B, Matusiewicz K, Iwańczak F. Clinical picture of classical, atypical and silent celiac disease in children and adolescents. Adv Clin Exp Med 2013; 22: 667-73.
40.
Ito MK, McGowan MP, Moriarty PM. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5 (3 Suppl): S38-45.
41.
Freedman DS, Mei Z, Srinivasan SR, Berenson GS, Dietz WH. Cardiovascular risk factors and excess adiposity among overweight children and adolescents: the Bogalusa Heart Study. J Pediatr 2007; 150: 12-17e2.
42.
Stolarz-Skrzypek K, Czarnecka D, Pietrzyk J. Prewencja miażdżycy u dzieci – rola statyn i kwasu acetylosalicylowego. Przegl Lek 2013; 70: 57-64.
43.
Sarkies M, Jones LK, Pang J, Sullivan D, Watts GF. How can implementation science improve the care of familial hypercholesterolaemia? Curr Atheroscler Rep 2023; 25: 133-43.
44.
Peterson A, McBride P. A review of guidelines for dyslipidemia in children and adolescents. WMJ 2012; 111: 274-81.
45.
Obarzanek E, Kimm SYS, Barton BA, et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children (DISC). Pediatrics 2001; 107: 256-64.
46.
Capra ME, Monopoli D, Decarolis NM, et al. Dietary models and cardiovascular risk prevention in pediatric patients. Nutrients 2023; 15: 3664.
47.
Andruszkiewicz K, Śliwińska A, Małgorzewicz S. Model żywienia osób z pierwotną hipercholesterolemią rodzinną. Forum Med Rodz 2014; 8: 127-34.
48.
Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016; 253: 281-344.
49.
Cicero AF, Colletti A, Bajraktari G, Descamps O, et al. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Arch Med Sci 2017; 13: 965-1005.
50.
Devaraj S, Jialal I. The role of dietary supplementation with plant sterols and stanols in the prevention of cardiovascular disease. Nutr Rev 2006; 64: 348-54.
51.
Musa-Veloso K, Poon TH, Elliot JA, Chung C. A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials. Prostaglandins Leukot Essent Fatty Acids 2011; 85: 9-28.
52.
Gylling H, Plat J, Turley S, et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 2014; 232: 346-60.
53.
Vuksan V, Jenkins AL, Rogovik AL, Fairgrieve CD, Jovanovski E, Leiter LA. Viscosity rather than quantity of dietary fibre predicts cholesterol-lowering effect in healthy individuals. Br J Nutr 2011; 106: 1349-52.
54.
Ribas SA, Cunha DB, Sichieri R, Santana Da Silva LC. Effects of psyllium on LDL-cholesterol concentrations in Brazilian children and adolescents: a randomised, placebo-controlled, parallel clinical trial. Br J Nutr 2015; 113: 134-41.
55.
Li Y, Jiang L, Jia Z, et al. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One 2014; 9: e98611.
56.
Guardamagna O, Abello F, Baracco V, Stasiowska B, Martino F. The treatment of hypercholesterolemic children: efficacy and safety of a combination of red yeast rice extract and policosanols. Nutr Metab Cardiovasc Dis 2011; 21: 424-9.
57.
Banderali G, Capra ME, Viggiano C, Biasucci G, Pederiva C. Nutraceuticals in paediatric patients with dyslipidaemia. Nutrients 2022; 14: 569.
58.
Di Donna L, De Luca G, Mazzotti F, et al. Statin-like principles of bergamot fruit (Citrus bergamia): isolation of 3-hydroxymethylglutaryl flavonoid glycosides. J Nat Prod 2009; 72: 1352-4.
59.
Cicero AFG, Fogacci F, Stoian AP, et al. Nutraceuticals in the management of dyslipidemia: which, when, and for whom? Could nutraceuticals help low-risk individuals with non-optimal lipid levels? Curr Atheroscler Rep 2021; 23: 57.
60.
Lee S, Lim HJ, Park JH, Lee KS, Jang Y, Park HY. Berberine-induced LDLR up-regulation involves JNK pathway. Biochem Biophys Res Commun 2007; 362: 853-7.
61.
Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004; 10: 1344-51.
62.
Cameron J, Ranheim T, Kulseth MA, Leren TP, Berge KE. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis 2008; 201: 266-73.
63.
Yu M, Jin X, Liang C, et al. Berberine for diarrhea in children and adults: a systematic review and meta-analysis. Therap Adv Gastroenterol 2020; 13: 1756284820961299.
64.
Doyon A, Kracht D, Bayazit AK, et al. Carotid artery intima-media thickness and distensibility in children and adolescents: reference values and role of body dimensions. Hypertension 2013; 62: 550-6.
65.
Daniels SR, Gidding SS, De Ferranti SD. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5 (3 Suppl): S30-7.
67.
Rosuvastatin – description of the substance – Drug Index MP. Available from: https://indeks.mp.pl/leki/desc....
68.
Atorvastatin – description of the substance – Drug Index MP. Available from: https://indeks.mp.pl/leki/desc....
71.
Avis HJ, Vissers MN, Stein EA, et al. A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2007; 27: 1803-10.
72.
Arambepola C, Farmer AJ, Perera R, Neil HAW. Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. Atherosclerosis 2007; 195: 339-47.
73.
Drzewoski J. Stosowanie statyn a ryzyko zachorowania na cukrzycę typu 2 – czy mamy się czego obawiać? Diabetol po Dypl 2010; 7: 48-9.
74.
O’Gorman CSM, O’Neill MB, Conwell LS. Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits. Vasc Health Risk Manag 2011; 7: 1-14.
75.
Ramaswami U, Humphries SE, Priestley-Barnham L, et al. Current management of children and young people with heterozygous familial hypercholesterolaemia – HEART UK statement of care. Atherosclerosis 2019; 290: 1-8.
76.
Dragan S, Serban MC, Banach M. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy? J Cardiovasc Pharmacol Ther 2015; 20: 157-68.
77.
Daniels S, Caprio S, Chaudhari U, et al. PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: the ODYSSEY KIDS study. J Clin Lipidol 2020; 14: 322-30.e5.
78.
Santos RD, Ruzza A, Hovingh GK, et al. Evolocumab in pediatric heterozygous familial hypercholesterolemia N Engl J Med 2020; 383: 1317-27.
79.
Mickiewicz A, Marlęga-Linert J, Fijałkowski M, Szymański F, Filipiak KJ, Gruchała M. Inklisiran – rewolucja w leczeniu hipercholesterolemii? Kardiol Inwazyjna 2021; 16: 150-4.
80.
Ray KK, Wright RS. Plain language summary of results from ORION-10 and ORION-11: two studies to learn how well inclisiran works in people with high cholesterol. Future Cardiol 2023; 19: 175-84.
81.
Ray KK, Troquay RPT, Visseren FLJ, et al. Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial. Lancet Diabetes Endocrinol 2023; 11: 109-9.
82.
Reijman MD, Schweizer A, Peterson ALH, et al. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. Eur J Prev Cardiol 2022; 29: 1361-8.
83.
Dziennik Ustaw – rok 2020 poz. 83 – INFOR.PL. Available from: https://www.infor.pl/akt-prawn....
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
